The first KRAS inhibitors to reach the clinic show preliminary but promising safety and efficacy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells
Stem Cell Research & Therapy Open Access 16 April 2024
-
Precision drugging of the MAPK pathway in head and neck cancer
npj Genomic Medicine Open Access 16 March 2022
-
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma
Journal of Experimental & Clinical Cancer Research Open Access 09 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Grail of RAS cancer drugs within reach. Nat Biotechnol 38, 6–8 (2020). https://doi.org/10.1038/s41587-019-0382-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0382-x
This article is cited by
-
Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells
Stem Cell Research & Therapy (2024)
-
Precision drugging of the MAPK pathway in head and neck cancer
npj Genomic Medicine (2022)
-
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma
Journal of Experimental & Clinical Cancer Research (2021)